drugset / Trial / NCT01090089
Combination of Lenalidomide and Dexamethasone in Treatment of Multiple Myeloma
Phase 3
Completed
348 enrolled
Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH
ClinAssess · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
In this study for elderly myeloma patients lenalidomide plus low-dose dexamethasone until progression is being compared with age-adjusted tandem high-dose melphalan 140 mg/m² augmented by induction with 3 cycles of lenalidomide plus low-dose dexamethasone before transplantation and lenalidomide maintenance after transplantation.
Timeline
- Start
- 2010-03-01
- Primary completion
- 2020-01-31
- Completion
- 2020-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Lenalidomide | Other / unclassified | 10 mg | — |
| Comparator | Lenalidomide | Other / unclassified | 25 mg | — |
| Subject | Melphalan | Small molecule | 140 mg/m2 | — |
| Comparator | Dexamethasone | Small molecule | 40 mg | Oral |